NASDAQ:GHRS - Nasdaq - IE000GID8VI0 - Common Stock - Currency: USD
NASDAQ:GHRS (5/2/2025, 2:03:53 PM)
11.135
+0.37 (+3.39%)
The current stock price of GHRS is 11.135 USD. In the past month the price increased by 3.56%. In the past year, price decreased by -7.79%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 59.99 | 782.55B | ||
JNJ | JOHNSON & JOHNSON | 15.5 | 375.48B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.96 | 306.56B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.72 | 225.24B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 19.44 | 224.19B | ||
MRK | MERCK & CO. INC. | 10.71 | 209.90B | ||
PFE | PFIZER INC | 7.54 | 137.19B | ||
SNY | SANOFI-ADR | 14.37 | 135.79B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.83 | 102.07B | ||
GSK | GSK PLC-SPON ADR | 7.04 | 78.44B | ||
ZTS | ZOETIS INC | 26.55 | 70.10B | ||
HLN | HALEON PLC-ADR | 21.87 | 48.35B |
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 49
Company Website: http://www.ghres.com
Investor Relations: https://investor.ghres.com/
Phone: 35314378334
The current stock price of GHRS is 11.135 USD. The price increased by 3.39% in the last trading session.
The exchange symbol of GH RESEARCH PLC is GHRS and it is listed on the Nasdaq exchange.
GHRS stock is listed on the Nasdaq exchange.
14 analysts have analysed GHRS and the average price target is 32.49 USD. This implies a price increase of 191.82% is expected in the next year compared to the current price of 11.135. Check the GH RESEARCH PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GH RESEARCH PLC (GHRS) has a market capitalization of 690.70M USD. This makes GHRS a Small Cap stock.
GH RESEARCH PLC (GHRS) currently has 49 employees.
GH RESEARCH PLC (GHRS) has a support level at 9.49 and a resistance level at 11.39. Check the full technical report for a detailed analysis of GHRS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GHRS does not pay a dividend.
GH RESEARCH PLC (GHRS) will report earnings on 2025-05-14.
GH RESEARCH PLC (GHRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
The outstanding short interest for GH RESEARCH PLC (GHRS) is 7.02% of its float. Check the ownership tab for more information on the GHRS short interest.
ChartMill assigns a technical rating of 4 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS turns out to be only a medium performer in the overall market: it outperformed 47.06% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. The financial health of GHRS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS decreased by -10.29% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.69% | ||
ROE | -21.77% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to GHRS. The Buy consensus is the average rating of analysts ratings from 14 analysts.